ÂÜÀòÂÒÂ×

David's discovery, together with the pharmacologic insights of Dr. Robert Kessler, led to a method of reversing desensitization to agonists at dopamine 2 and 3 receptor subtypes, the company’s powerful platform in neuropharmacology. David is a Distinguished Fellow of the American Board of Psychiatry and Neurology, having conducted extensive research in neurological psychiatry with Norman Geschwind, the late James Jackson Professor of Neurology at Harvard Medical School. He is a graduate of Harvard College and Harvard Medical School, a Fellowship at NINDS, and completed his Psychiatric Residency at MGH. He served on the faculties of Harvard, Vanderbilt, and the University of Massachusetts Medical Schools, where he was Professor of Psychiatry.